Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
151 hedge funds and large institutions have $328M invested in Eagle Pharmaceuticals, Inc. in 2022 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 59 increasing their positions, 47 reducing their positions, and 19 closing their positions.
11,773% more call options, than puts
Call options by funds: $1.78M | Put options by funds: $15K
26% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 47
8% more capital invested
Capital invested by funds: $304M → $328M (+$23.9M)
5% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 19
1% less funds holding
Funds holding: 153 → 151 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSV Asset Management
Chicago,
Illinois
|
+$4.81M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.77M |
| 3 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
+$2.71M |
| 4 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$1.99M |
| 5 |
HF
HRT Financial
New York
|
+$1.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$3.83M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.53M |
| 3 |
Millennium Management
New York
|
-$2.39M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.27M |
| 5 |
State Street
Boston,
Massachusetts
|
-$1.9M |
EGRX Hedge Fund Activity: Q4 2022 in Review
151 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q4 2022, worth a combined $328M — up 7.9% from $304M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new EGRX positions and 19 closed out — a net gain of 1 holder — while 59 added to existing stakes and 47 trimmed.
The largest buyer was LSV Asset Management, opening a new position worth an estimated $4.81M. The largest seller was JP Morgan Chase, cutting an estimated $3.83M.
- 151 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q4 2022, down from 153 in Q3 2022.
- Funds reported $328M of Eagle Pharmaceuticals, Inc. stock for Q4 2022, up 7.9% quarter-over-quarter.
- 20 funds opened new Eagle Pharmaceuticals, Inc. positions in Q4 2022 and 19 closed out, a net change of +1 holder.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q4 2022 was LSV Asset Management, an estimated $4.81M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q4 2022 was JP Morgan Chase, an estimated $3.83M sold.
Based on aggregated 13F filings for Q4 2022.